Loading cancer entity…
Loading cancer entity…
Clinical trials
296 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (43)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03101748 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06408168 | Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial) | terminated | Phase 2 | 6 | M.D. Anderson Cancer Center |
| 1 |
| Jan 5, 2026 |
| clinicaltrials |
| NCT03979508 | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer | terminated | Phase 2 | 26 | Mayo ClinicOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT05041101 | Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer | terminated | Phase 1 / Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT04252859 | [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma | terminated | Phase 2 | 44 | University of UtahOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT01938833 | Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer | terminated | Phase 1 / Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT03872388 | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT02658812 | Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT02137252 | Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer | terminated | Phase 2 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT03184558 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC | terminated | Phase 2 | 29 | BerGenBio ASAINDUSTRY | 4 | Nov 9, 2021 | clinicaltrials |
| NCT01934335 | Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer | terminated | Phase 2 | 12 | Ronald WeigelOTHER | 1 | Nov 1, 2021 | clinicaltrials |
| NCT02892734 | Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer | terminated | Phase 2 | 3 | Northwestern UniversityOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT02365714 | CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)(CK-SAPBI) | terminated | Phase 1 / Phase 2 | 2 | Georgetown UniversityOTHER | 1 | Apr 13, 2018 | clinicaltrials |
| NCT01754519 | Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery | terminated | Phase 2 | 1 | Roswell Park Cancer InstituteOTHER | 1 | Jul 7, 2017 | clinicaltrials |
| NCT00148720 | Capecitabine in Women With Operable Breast Cancer | terminated | Phase 2 | 80 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 11, 2015 | clinicaltrials |
| NCT01194427 | A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer | terminated | Phase 2 | 2 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 17, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Feb 12, 2026source: clinicaltrials